Less than half of Americans newly diagnosed with myasthenia gravis (MG) are receiving the recommended blood tests to confirm their condition, even though these results are vital for choosing the appropriate treatment. According to new research using real-world U.S. insurance data, many patients are starting MG-specific therapies, including…
News
Aiming to address a persistent gap in myasthenia gravis (MG) research, Vitaccess is teaming up with the Myasthenia Gravis Foundation of America (MGFA) to expand real-world data collection in MG. As part of the new exclusive agreement, MGFA will become the official collaborator for the Vitaccess Real MG…
Uplizna (inebilizumab), Amgen’s infusion therapy for adults with generalized myasthenia gravis (gMG) who are positive for antibodies targeting acetylcholine receptor (AChR) or muscle-specific kinase (MuSK), is now approved for use in the European Union. The decision by the European Commission — which applies to all EU member states…
Standard treatments helped many people with myasthenia gravis (MG) who lack the most common disease-causing antibodies, according to a new review study. The findings shed new light on how so-called double-seronegative MG (dSNMG) compares with more common forms of the disease and highlight the need for careful monitoring,…
Tofacitinib, an approved medication for some types of inflammatory arthritis and inflammatory bowel disease, improves muscle strength, daily functioning, and quality of life in people with hard-to-treat myasthenia gravis (MG), according to a small pilot clinical trial. Slightly more than half of the participants experienced few or no symptoms…
A new digital platform — MyaLink — enables doctors to monitor the physical and mental health of people with myasthenia gravis (MG) in real time and communicate directly with patients through the app, a study shows. Data collected by MyaLink on MG patients’ symptoms, disease activity, daily functioning, and…
Robotic thymectomy — a surgical removal of the thymus gland using robotic systems — is an effective and safe treatment for people with late-onset myasthenia gravis (MG), including those who develop the rare neuromuscular disease after the age of 65, according to a two-decade-long study in China. Rates…
A single course of six once-weekly infusions of Descartes-08, an investigational CAR T-cell therapy, was well tolerated and resulted in sustained clinically meaningful responses in people with generalized myasthenia gravis (gMG). That’s according to final data from the Phase 2b MG-001 clinical trial (NCT04146051), which also showed…
People with myasthenia gravis (MG) who take corticosteroids, especially at higher cumulative doses, face an increased risk of developing other health conditions, according to a study in the U.S. Patients are at risk for conditions including diabetes, infections, and cardiovascular diseases, the researchers found. “Our findings highlight the importance…
A new study shows how Cour Pharmaceuticals‘ nanoparticle platform is able to modulate immune system activity, lending support for the company’s experimental treatments. Cour’s CNP-106, an experimental treatment for generalized myasthenia gravis, is currently being tested in a Phase 1b/2a clinical trial (NCT06106672), which may still be…
Recent Posts
- One troubling aspect of chronic illness is when I find myself losing empathy
- Most MG patients in US start therapy without lab confirmation of disease
- Even with myasthenia gravis, ‘you still have to get up in the morning’
- New patient registry aims to collect real world evidence on MG in US
- Amgen’s Uplizna now approved in EU to treat most adults with gMG